State Key Laboratory of Molecular Oncology (SKLMO)

2016-09-18

Founded in November 1988,The State Key Laboratory of Molecular Oncology (SKLMO) is an open basic research institute of cancer studies.  Professor Wu Min, academician of the Chinese Academy of Sciences, served as the first-term director of the laboratory. Zhan Qimin is the current director and Zhang Xuemin is the chair of the academic committee. SKLMO has 62 full-time staff members, including 47 researchers: 30 with senior professional titles, 13 deputy senior and 4 assistant researchers; 13 technical staff, among whom, 2 are associate senior technologists and 11 principal technologists; 2 administrators. The laboratory has 17 research groups and a technical center.


SKLMO is home to many talents, including 2 academicians of Chinese Academy of Sciences, 3 academicians of Chinese Academy of Engineering, 3 professors from Changjiang Scholars Program of Minister of education, one from the national Thousand Talents Plan, 2 scientists from the Thousand Talent Youth program, one scholar from the Innovative Talents Promotion Plan, 6 winners of National Science Fund for Outstanding Young Scholars, 4 recipients of the National Science Fund for Distinguished Oversea Young Scholars, 5 candidates (with one newly selected) from the national New Century Bai-Qian-Wan Talented Personnel Project, and 3 specialists from the list of “Middle-aged and Young Leading Talents in Scientific and Technical Innovation” selected by the Ministry of Health. The laboratory has the NNSF "molecular oncology research" innovation group, the innovation team of Ministry of Education and a key-area innovation team of Ministry of Science and Technology.



The State Key Laboratory of Molecular Oncology is affiliated with the Cancer Hospital of Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC).


The research focuses of the State Key Laboratory of Molecular Oncology are to investigate the impact of genetic factors on tumorigenesis and explore the interactions between genetic factors and environmental stimuli; to determine the roles of cell cycle control, apoptosis and related cell signalings in the maintenance of genomic fidelity, and seek for the molecular mechanisms by which genomic instability contributes to cell transformation and carcinogenesis; to carry out studies on genetic/molecular epidemiology, cytogenetics and molecular genetics in the high-incidence areas for esophageal or liver cancers, and to identify biomarkers and gene/protein profiles for cancer early diagnosis, cancer therapy and prognosis. SKLMO aims to apply the cutting-edge medical science in China's actual situation, targeting at the most common malignancy of esophageal cancer, liver cancer in areas such as Yangquan in Shanxi and Qidong in Jiangsu, so as to develop a more rational design as well as effective methods in prevention and treatment to reduce the morbidity and mortality rate in these areas.



In the past five years, the lab has undertaken several major projects of national science programs, such as 973 Projects, 863 Programs and the Natural Science Foundation, pioneering in the researches in genetic etiology of esophageal cancer (genetic susceptibility), scale-up prevention strategies, tumor suppressor gene cloning, genome-wide scan and the various stages and their corresponding function of the cancer genome expression profiling.


    


Within five years, SKLMO has 274 papers published by SCI, among these papers, 217 articles with SKLMO as the first author/unit and/or corresponding author and 10 articles with IF>30, (one article inNature, 9 papers inNature Genetics). According to JCR journals online query platform, a total of 36 papers are published in Zone 1 in the medical and biological areas, accounting for 16.6% of the total number of papers.